GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
120.79
-4.60 (-3.67%)
As of 10:17AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close125.39
Open120.91
Bid120.64 x 800
Ask120.87 x 1000
Day's Range117.74 - 121.47
52 Week Range105.12 - 179.65
Volume189,038
Avg. Volume577,213
Market Cap3.907B
Beta (3Y Monthly)4.01
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire18 hours ago

    GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, announced today that results from completed Phase 3 trials of EPIDIOLEX® (cannabidiol) oral solution CV, as well as new pre-clinical and Phase 1 cannabinoid research, will be presented at the American Epilepsy Society (AES) Annual Meeting, November 30-December 4, 2018, in New Orleans, Louisiana. EPIDIOLEX is FDA-approved and available by prescription in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older.

  • ACCESSWIREyesterday

    4 Marijuana Stocks Expanding Across North America

    China trade and the looming Russia medalling that continues to surround the White House have had a wild impact on markets. One industry that is not only used to volatility but one that is also seeing growing interest from investors has been the cannabis industry. Slated as an expanding sector, marijuana stocks have had a long-standing role in the spotlight for its risqué impact on society.

  • ACCESSWIRE7 days ago

    Election Night Cannabis Approvals Could Benefit These Companies

    HENDERSON, NV / ACCESSWIRE / November 13, 2018 / Last Tuesday's election was great news for cannabis companies. With Michigan approving recreational marijuana and several other measures passing investors ...

  • ACCESSWIRE14 days ago

    CBD Stocks on The Rebound

    HENDERSON, NV / ACCESSWIRE / November 6, 2018 / As the stock market plummeted early October cannabis companies stayed strong, buoyed up by legislative changes in Canada. The cannabis market appears set ...

  • GlobeNewswire14 days ago

    GW Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results and Host Conference Call on 27 November, 2018

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 27 November, 2018 its fourth quarter and year-end financial results for the period ending 30 September, 2018. GW will also host a conference call the same day at 4:30 p.m. EST. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

  • ACCESSWIRE18 days ago

    Friday's Top Trending Marijuana Stocks

    CORAL GABLES, FL / ACCESSWIRE / November 2, 2018 / During the second half of the week, marijuana stocks rallied after weeks of downward movement. The cannabis industry was joined by Britain and other reports ...

  • ACCESSWIRE19 days ago

    Oversold CBD Stocks

    HENDERSON, NV / ACCESSWIRE / November 1, 2018 / Last week, Marijuana stocks saw a steep selloff as investors took profits after the big legalization event in Canada. At this point there are plenty of CBD ...

  • GlobeNewswire19 days ago

    EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral solution CV is now available in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. EPIDIOLEX, which was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018, is the first prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs.

  • ACCESSWIRE27 days ago

    This CBD Stock Soared Over 2000%

    HENDERSON, NV / ACCESSWIRE / October 24, 2018 / While several cannabis companies have pulled back this week, this has made for some tasty buy opportunities. None more enticing to us than Real Brands, Inc. ...

  • GlobeNewswirelast month

    Investor Expectations to Drive Momentum within Motorola Solutions, Shire plc, Bitauto, GRIDSUM HOLDING, GW Pharmaceuticals, and Actinium Pharmaceuticals — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRElast month

    Stocks in Position to Beat the Failing Market

    HENDERSON, NV / ACCESSWIRE / October 18, 2018 / There has been some bad news in the market recently causing some securities to sell off. This has made for some desirable buying opportunities for savvy ...

  • ACCESSWIRElast month

    Why This Company is Set for a Major Breakout

    HENDERSON, NV / ACCESSWIRE / October 15, 2018 / With the broader market tanking it is likely investors will find safe haven in cannabis and biotech stocks because they are both innovative sectors. An incredibly ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Aerie Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...

  • ACCESSWIRElast month

    Top Beverage Companies Entering CBD

    HENDERSON, NV / ACCESSWIRE / October 10, 2018 / Molson Coors became the latest major beverage company to announce plans to start their own CBD beverage arm. Coca-Cola and InBev have also announced similar ...

  • ACCESSWIRE2 months ago

    Cannabis Industry Service Provider Solving Major Challenges

    HENDERSON, NV / ACCESSWIRE / October 5, 2018 / One of the major reasons cannabis stocks are doing so well is because they are potential solutions to long standing challenges, such as the opioid epidemic. ...

  • GlobeNewswire2 months ago

    GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs, Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs

    GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of 1,900,000 American Depositary Shares (“ADSs”) and the full exercise by the underwriters of their option to purchase 285,000 additional ADSs from GW at a price to the public of $158.00 per ADS, raising gross proceeds of $345,230,000 (before deducting underwriting discounts, commissions and offering expenses).

  • GlobeNewswire2 months ago

    GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million

    GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company.

  • ACCESSWIRE2 months ago

    DEA Rescheduling Makes CBD Stocks Blazing Hot

    HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The DEA has just made a move that makes that has investors fired up.Last week, U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval. The agency announced Thursday that drugs including "finished dosage formulations" of CBD with THC below 0.1% will be considered Schedule 5 drugs, as long as the medications have been approved by the U.S. Food and Drug Administration. This has made CBD stocks even hotter than they have been.CBD stallwarts like GW Pharma, who was a large reason for this ruling are obviously benefitting, however, for investors looking to maximize their profit potential from this ruling it's beneficial to dig a little deeper.

  • GlobeNewswire2 months ago

    GW Pharmaceuticals Announces Proposed Public Offering of ADSs

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform and whose U.S. subsidiary is Greenwich Biosciences, announced today that it intends to sell, subject to market and other conditions, $300 million of American Depositary Shares (“ADSs”) representing ordinary shares of GW on the Nasdaq Global Market in an underwritten U.S. public offering.  GW expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of ADSs at the offering price. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • ACCESSWIRE2 months ago

    The Hottest CBD Stocks

    HENDERSON, NV / ACCESSWIRE / October 1, 2018 / With the DEA rescheduling CBD the top is off, and the time is now to find CBD companies before missing the boat.CBD is a very lucrative business, because ...

  • ACCESSWIRE2 months ago

    3 Marijuana Stocks That Could Close Your Week With A Bang

    CORAL GABLES, FL / ACCESSWIRE / September 28, 2018 / It's no secret that marijuana stocks are capturing a lot of attention lately and because of this, it's no wonder why one of the few cannabis ETFs that track the industry, the ETFMG Alternative Harvest ETF (MJ), has jumped by more than 30% since March. Alcoholic-beverage maker Constellation Brands' $4 billion investment in Canadian marijuana company Canopy Growth was a big catalyst in recent weeks. This was followed up by a number of other companies like Molson Coors and even Coca-Cola eyeing the cannabis market.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: GW Pharmaceuticals and Tilray

    NEW YORK, NY / ACCESSWIRE / September 28, 2018 / Shares of pot stocks were on the move in Thursday's session after exciting news from British biopharmaceutical company GW Pharmaceuticals. Shares of GW as well as Tilray climbed higher as traders celebrated. GW Pharmaceuticals plc shares were up almost 7% on Thursday after exciting news about the U.S. Drug Enforcement Administration (DEA).

  • ACCESSWIRE2 months ago

    3 Marijuana Stocks Heading Higher In October 2018

    CORAL GABLES, FL / ACCESSWIRE / September 27, 2018 / November's midterm elections will mark two years since Donald Trump's 2016 Presidential win and the first test of how his Republican party is performing in the eyes of the American public. With this will come the buzz around cannabis legalization in the US. Texas could see pro-legalization Beto O'Rourke add a new support to the US Senate.

  • GlobeNewswire2 months ago

    GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce the DEA has Rescheduled EPIDIOLEX® (cannabidiol) Oral Solution to Schedule V

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S. Drug Enforcement Administration (DEA). EPIDIOLEX, which was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older, is the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs (AEDs).

  • ACCESSWIRE2 months ago

    Medical Cannabis and Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / September 26, 2018 / Two of the most visible sectors on the market recently have been Medical Cannabis and Biotech, respectively. The demonstrated frequency of innovative breakthroughs ...